<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01816334</url>
  </required_header>
  <id_info>
    <org_study_id>1201</org_study_id>
    <nct_id>NCT01816334</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica</brief_title>
  <acronym>TéAGS</acronym>
  <official_title>Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether anti-inflammatory drugs or glucocorticoids
      are effective in the treatment of acute sciatica
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean visual analogue scale (VAS) for leg pain (radicular pain) in 3 groups</measure>
    <time_frame>From day 0 to day 5</time_frame>
    <description>VAS is measured in millimiters (0 to 100). This pain score is recommended in rheumatologic units in France.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean visual analogue scale (VAS) for back pain in 3 groups</measure>
    <time_frame>From day 0 to day 5</time_frame>
    <description>VAS is measured in millimeters (0 to 100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess drug compliance</measure>
    <time_frame>From day 0 to day 5</time_frame>
    <description>Drug compliance is estimated based on the proportion of the treatment actually administered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The effect of treatment on the EIFEL Questionnaire</measure>
    <time_frame>At baseline, 1 and 3 months after intervention</time_frame>
    <description>The EIFEL questionnaire is the translation of the Roland Morris Disability Questionnaire (RMDQ) and has been validated in acute low back pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Lasegue's sign compared to baseline</measure>
    <time_frame>At baseline, Day 1,2,3,4 and 5 of study period</time_frame>
    <description>Lasegue's sign is the lumbar pain experienced by the patient on passive movement of the legs during flexion of hip joint i.e. passive straight leg raising. It is assessed as either 'Positive' or 'Negative' sign.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Schober's test</measure>
    <time_frame>From Day 0 to Day 5</time_frame>
    <description>Schober's test is a test used in rheumatology to measure the ability of patient to flex their lower back</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>At baseline, day 0, 1, 2, 3, 4 and day 5, 1 and 3 months</time_frame>
    <description>Analgesic consumption between active treatment group and placebo group was registered and differences between groups were calculated and presented as percentual differences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery or lumbar epidural injection</measure>
    <time_frame>At 1 and 3 months after intervention</time_frame>
    <description>Number of patient having surgery and/or lumbar epidural injection during study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical tolerance: adverse events and/or high blood pressure</measure>
    <time_frame>at baseline, day 1, 2 3, 4 and 5</time_frame>
    <description>Number of adverse events and/or high blood pressure between intervention group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological tolerance</measure>
    <time_frame>at baseline, day 3 and 5</time_frame>
    <description>measures of leukocytes, erythrocytes, hemoglobin, platelets, serum sodium, potassium, glucose, plasma creatinine between intervention group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic levels</measure>
    <time_frame>at baseline, day 1 to 5</time_frame>
    <description>monitoring of glycemic status is measured for each day of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of hospitalisation sick leave, number of days lost to illness</measure>
    <time_frame>At baseline, 1 and 3 months</time_frame>
    <description>To assess the cost of sciatica for society</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 60 mg of methylprednisolone at 8:00 am and 100 ml of 0.9 % sodium chloride (placebo) at 6:00 pm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketoprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>administration of 100 mg of ketoprofen at 8:00 am and at 6:00 pm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium chloride</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>administration of 100 ml of 0.9% sodium chloride (placebo) at 8:00 am and at 6:00 pm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <arm_group_label>methylprednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoprofen</intervention_name>
    <arm_group_label>Ketoprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <arm_group_label>methylprednisolone</arm_group_label>
    <arm_group_label>sodium chloride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  sciatica &lt;8 weeks resistant to all treatments in ambulatory

          -  Acute low back pain&gt; 48 hours;

          -  Non-deficit patients;

          -  Initial VAS&gt; 40/100;

          -  Consent of patient

          -  Conflict disco-radicular concordance with the clinical computed tomography scan or
             magnetic resonance imaging.

          -  No of contraindications to methylprednisolone, ketoprofen;

          -  No registration to another protocol;

        Exclusion Criteria:

          -  Pregnant, parturient, lactating mother;

          -  Diabetic patient;

          -  Patient with syndrome from narrowing of the lumbar vertebral canal

          -  Patient with a history of lumbar surgery &lt;1 year;

          -  Patient with a Cauda equina syndrome or major motor disability;

          -  Crural neuralgia

          -  Patient with a deficit;

          -  Suspicion of sciatica secondary, ie not conflict-related disco-root: infectious
             neuritis, fracture on spinal bone tumor ...

        associated treatment or pathology contra-indicating administration methylprednisolone,
        ketoprofen.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Hôpital Sud</name>
      <address>
        <city>Echirolles</city>
        <zip>38130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Uriage</name>
      <address>
        <city>Uriage</city>
        <zip>38410</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Roncoroni C, Baillet A, Durand M, Gaudin P, Juvin R. Efficacy and tolerance of systemic steroids in sciatica: a systematic review and meta-analysis. Rheumatology (Oxford). 2011 Sep;50(9):1603-11. doi: 10.1093/rheumatology/ker151. Epub 2011 Apr 27. Review.</citation>
    <PMID>21525139</PMID>
  </reference>
  <reference>
    <citation>Chou R, Huffman LH; American Pain Society; American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007 Oct 2;147(7):505-14. Review. Erratum in: Ann Intern Med. 2008 Feb 5;148(3):247-8.</citation>
    <PMID>17909211</PMID>
  </reference>
  <reference>
    <citation>Vroomen PC, de Krom MC, Slofstra PD, Knottnerus JA. Conservative treatment of sciatica: a systematic review. J Spinal Disord. 2000 Dec;13(6):463-9.</citation>
    <PMID>11132976</PMID>
  </reference>
  <reference>
    <citation>Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of non-steroidal anti-inflammatory drugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis. 1997 Apr;56(4):214-23. Review.</citation>
    <PMID>9165992</PMID>
  </reference>
  <reference>
    <citation>Luijsterburg PA, Verhagen AP, Ostelo RW, van Os TA, Peul WC, Koes BW. Effectiveness of conservative treatments for the lumbosacral radicular syndrome: a systematic review. Eur Spine J. 2007 Jul;16(7):881-99. Epub 2007 Apr 6. Review.</citation>
    <PMID>17415595</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2013</study_first_posted>
  <last_update_submitted>March 23, 2016</last_update_submitted>
  <last_update_submitted_qc>March 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sciatica</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Glucocorticoids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Ketoprofen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

